Literature DB >> 26450096

[Vertebral metastases of urogenital carcinomas: Diagnosis and conservative therapy].

B Keck1, M Hammon2, M Uder2, J Huber3, P J Goebell4, F Kunath4, B Wullich4, R H Richter5.   

Abstract

The high incidence of bone metastases of urologic neoplasms and their morbidity, especially of vertebral metastases, requires exact diagnosis and consequent therapy. Conventional radiography plays an important role in the diagnosis of symptomatic bone lesions. Computed tomography can evaluate the stability of metastatic lesions and is indispensable for therapy planning. MRI and PET-CT have the highest diagnostic accuracy for the detection of bone metastases and MRI can evaluate their intra- and extraosseus components. PET-CT, PET-MRI, or SPECT-CT in combination with specific tracers - due to their high specificity and sensitivity - have the potential to replace conventional methods in the future. Conservative treatment basically consists of analgesic therapy, the administration of calcium and vitamin D3 and bisphosphonates or inhibitors of RANKL (denosumab). Moreover radium-223-dichloride can improve overall survival and the time to the first symptomatic skeletal event in castration-resistant prostate cancer patients with bone metastases.

Entities:  

Keywords:  Bone lesions, symptomatic; Denosumab; Radium 223 dichloride; Vertebral metastases; Zoledronic-acid

Mesh:

Substances:

Year:  2016        PMID: 26450096     DOI: 10.1007/s00120-015-3977-y

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  32 in total

1.  Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.

Authors:  Varun Shandal; Rakesh Kumar
Journal:  BJU Int       Date:  2010-07       Impact factor: 5.588

Review 2.  Diagnosis of bone metastases: a meta-analysis comparing ¹⁸FDG PET, CT, MRI and bone scintigraphy.

Authors:  Hui-Lin Yang; Tao Liu; Xi-Ming Wang; Yong Xu; Sheng-Ming Deng
Journal:  Eur Radiol       Date:  2011-09-02       Impact factor: 5.315

Review 3.  Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease.

Authors:  H L Neville-Webbe; R E Coleman
Journal:  Eur J Cancer       Date:  2010-03-27       Impact factor: 9.162

Review 4.  Treatment of bone metastases in urologic malignancies.

Authors:  Michael Froehner; Tobias Hölscher; Oliver W Hakenberg; Manfred P Wirth
Journal:  Urol Int       Date:  2014-08-07       Impact factor: 2.089

Review 5.  The treatment of spinal metastases.

Authors:  Karl-Stefan Delank; Clemens Wendtner; Hans Theodor Eich; Peer Eysel
Journal:  Dtsch Arztebl Int       Date:  2011-02-04       Impact factor: 5.594

Review 6.  Radiological imaging for the diagnosis of bone metastases.

Authors:  L D Rybak; D I Rosenthal
Journal:  Q J Nucl Med       Date:  2001-03

Review 7.  Prostate-specific membrane antigen-based imaging.

Authors:  Joseph R Osborne; Naveed H Akhtar; Shankar Vallabhajosula; Alok Anand; Kofi Deh; Scott T Tagawa
Journal:  Urol Oncol       Date:  2012-05-31       Impact factor: 3.498

8.  Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

Authors:  Karim Fizazi; Allan Lipton; Xavier Mariette; Jean-Jacques Body; Yasmin Rahim; Julie R Gralow; Guozhi Gao; Ling Wu; Winnie Sohn; Susie Jun
Journal:  J Clin Oncol       Date:  2009-02-23       Impact factor: 44.544

9.  Assessing the relation between bone marrow signal intensity and apparent diffusion coefficient in diffusion-weighted MRI.

Authors:  Anwar R Padhani; Katherine van Ree; David J Collins; Shirley D'Sa; Andreas Makris
Journal:  AJR Am J Roentgenol       Date:  2013-01       Impact factor: 3.959

10.  [Surgical management of vertebral column metastatic disease].

Authors:  K-D Schaser; I Melcher; T Mittlmeier; A Schulz; J H Seemann; N P Haas; A C Disch
Journal:  Unfallchirurg       Date:  2007-02       Impact factor: 1.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.